VAM
ZVRA icon

Visium Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Visium Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-17,375
Closed -$5.11M – 1214
2015
Q2 		$5.11M Buy
+17,375
New +$3.79M 0.07% 278

Other funds holding ZVRA

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Visium Asset Management's ZVRA Position: Q3 2015 in Review

Visium Asset Management sold out of Zevra Therapeutics (ZVRA) in Q3 2015, closing a stake of 17,375 shares — an estimated $5.11M sold.

Visium Asset Management first reported a position in ZVRA in Q2 2015 and held it in 1 quarter. The position peaked at $5.11M in Q2 2015. 33 funds tracked by Wall St. Rank hold ZVRA as of Q3 2015.

  • Visium Asset Management reported no remaining Zevra Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Visium Asset Management sold 17,375 Zevra Therapeutics shares in Q3 2015, an estimated $5.11M.
  • Visium Asset Management first reported a position in Zevra Therapeutics in Q2 2015 and held it in 1 quarter.
  • Visium Asset Management's Zevra Therapeutics position peaked at $5.11M in Q2 2015.
  • 33 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2015.

Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.